BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3784610)

  • 21. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
    Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
    Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Surgical management of orbital malignant melanoma: our experience and a report of three cases].
    Poli T; Mora P; Reichegger V; Ricci R; Corradi D; Gandolfi SA; Sesenna E
    Klin Monbl Augenheilkd; 2007 Oct; 224(10):794-8. PubMed ID: 17952825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
    Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
    Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients.
    Kuczyk M; Machtens S; Hradil K; Schubach J; Christian W; Knüchel R; Hartmann J; Bokemeyer C; Jonas U; Serth J
    Br J Cancer; 1999 Nov; 81(6):1052-8. PubMed ID: 10576664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphokine-mediated immunotherapy studies in mouse tumor systems.
    Papermaster BW; Gilliland CD; McEntire JE; Smith ME; Buchok SJ
    Cancer; 1980 Mar; 45(5 Suppl):1248-53. PubMed ID: 7357517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cancer immunotherapy].
    Kaartinen M; Mäkelä O
    Duodecim; 1976; 92(24):1364-9. PubMed ID: 1070434
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunomodulators as local hormones: new insights regarding their clinical utilization.
    Bocci V
    J Biol Response Mod; 1985 Aug; 4(4):340-52. PubMed ID: 2411878
    [No Abstract]   [Full Text] [Related]  

  • 30. Lymphokine gene therapy for cancer.
    Russell SJ
    Immunol Today; 1990 Jun; 11(6):196-200. PubMed ID: 2191681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic potential of lymphokines in neoplastic disease.
    Pulley MS; Dumonde DC
    Ann N Y Acad Sci; 1988; 521():274-89. PubMed ID: 3288044
    [No Abstract]   [Full Text] [Related]  

  • 32. On lymphokines, cytokines, and breakthroughs.
    Moertel CG
    JAMA; 1986 Dec; 256(22):3141. PubMed ID: 3537345
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
    Wolf GT; Fee WE; Dolan RW; Moyer JS; Kaplan MJ; Spring PM; Suen J; Kenady DE; Newman JG; Carroll WR; Gillespie MB; Freeman SM; Baltzer L; Kirkley TD; Brandwein HJ; Hadden JW
    Head Neck; 2011 Dec; 33(12):1666-74. PubMed ID: 21284052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.
    Pulley MS; Nagendran V; Edwards JM; Dumonde DC
    Lymphokine Res; 1986; 5 Suppl 1():S157-63. PubMed ID: 3784610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lymphokines in tumour-bearing patients: clinical and laboratory studies.
    Dumonde DC; Pulley MS; Southcott BM; den Hollender FC
    Prog Clin Biol Res; 1983; 132E():83-93. PubMed ID: 6647491
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
    Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
    Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
    Adler A; Stein JA; Kedar E; Naor D; Weiss DW
    J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical applications of sentinel lymph-node biopsy for the staging and treatment of solid neoplasms.
    Gipponi M
    Minerva Chir; 2005 Aug; 60(4):217-33. PubMed ID: 16166921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.